Attending the [conference] was an exceptional experience. The format of engaging, evidence-based debates between leading experts truly set this event apart from traditional conferences. Each session challenged my thinking, encouraged deeper clinical insight, and provided practical takeaways I could take to my team. The lively discussions, combined with access to the latest research and evolving standards of care, made this a must-attend event for any clinician in the hematology / oncology fields. I left feeling inspired, informed, and better equipped to deliver optimal care to my patients."
Available Dates
June 27-28, 2026 | New York City | Register Now
July 25-26, 2026 | Dallas | Register Now
Turning Controversies into Clarity
Turning Controversies into Clarity
LL&M Great Debates
With new data and approvals emerging fast, we need more than summaries—we need conversations.
Hematology moves fast, data shifts, standards evolve, and the right next step isn’t always clear. LL&M Great Debates was built for the gray area between what’s known and what’s still being tested.
Across leukemia, lymphoma, myeloma, and chronic lymphocytic leukemia, experts take opposing positions on key questions in hematologic malignancy care. Each debate explores the evidence and challenges assumptions, examining how new data will apply to real-world practice. The discussions go beyond presentations to expose the reasons behind each approach and help you weigh the data in context to gain a deeper understanding of treatment decisions.
Debates form the foundation of the program, complemented by roundtables, case-based discussions, and audience Q&A. Every session is designed to clarify uncertainty in disease management and turn emerging evidence into practical guidance you can use the next day with your patients. Attendees often find that the dialogue helps define what matters most in their daily practice and informs how they interpret the latest research.
This conference covers the full spectrum of blood cancers, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL). Each topic is discussed by leaders in the field who bring both research and clinical perspectives to the table.
Whether you are looking to update your clinical knowledge, earn CE credit, or connect with peers, LL&M Great Debates series provides an interactive environment focused on improvements in patient outcomes.
Hematology moves fast, data shifts, standards evolve, and the right next step isn’t always clear. LL&M Great Debates was built for the gray area between what’s known and what’s still being tested.
Across leukemia, lymphoma, myeloma, and chronic lymphocytic leukemia, experts take opposing positions on key questions in hematologic malignancy care. Each debate explores the evidence and challenges assumptions, examining how new data will apply to real-world practice. The discussions go beyond presentations to expose the reasons behind each approach and help you weigh the data in context to gain a deeper understanding of treatment decisions.
Debates form the foundation of the program, complemented by roundtables, case-based discussions, and audience Q&A. Every session is designed to clarify uncertainty in disease management and turn emerging evidence into practical guidance you can use the next day with your patients. Attendees often find that the dialogue helps define what matters most in their daily practice and informs how they interpret the latest research.
This conference covers the full spectrum of blood cancers, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL). Each topic is discussed by leaders in the field who bring both research and clinical perspectives to the table.
Whether you are looking to update your clinical knowledge, earn CE credit, or connect with peers, LL&M Great Debates series provides an interactive environment focused on improvements in patient outcomes.
Conference Co-Chairs
-
Jessica K AltmanJessica Altman, MD, is Professor in the Division of Hematology/Oncology at... -
John P LeonardJohn P. Leonard, M.D., is the Laura and Isaac Perlmutter Professor of... -
Joseph R. MikhaelDr Mikhael is a Professor in the Clinical Genomics and Therapeutics...
-
Emeritus ChairMorton ColemanDr Morton Coleman has been an Attending Physician at the New York...
Explore Our Other Events
What to Expect
What-to-Expect
- What is LL&M Great Debates?
LL&M Great Debates is an interactive hematology meeting built around point counterpoint discussions, audience questions, and case based dialogue. Rather than a series of lectures, the program focuses on real clinical uncertainty across leukemia, lymphoma, myeloma, and CLL. Faculty examine evidence from different angles to help clarify the choices clinicians face in practice.
- Who should attend LL&M Great Debates?
The meeting is designed for the full hematology care team, including physicians, APPs, pharmacists, nurses, researchers, and trainees. Whether someone focuses on leukemia, lymphoma, myeloma, or CLL, the agenda offers debates and roundtables that support daily clinical decisions.
- How does LL&M Great Debates connect with LL&M Congress?
LL&M Great Debates is part of the broader LL&M educational ecosystem. While LL&M Congress provides a multi day update across four disease focused programs each fall, LL&M Great Debates offers a concentrated forum earlier in the year where complex questions are worked through in discussion. Together, they create a year round learning pathway for hematology professionals.
-
Keep Me Updated
Back to top